AngioDynamics, Inc. (NASDAQ:ANGO) Sees Large Decline in Short Interest

AngioDynamics, Inc. (NASDAQ:ANGO) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totalling 2,250,000 shares, a decrease of 8.5% from the March 15th total of 2,460,000 shares. Based on an average trading volume of 575,400 shares, the days-to-cover ratio is currently 3.9 days.

Analyst Ratings Changes

ANGO has been the topic of several research reports. Raymond James dropped their price objective on shares of AngioDynamics from $12.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 9th. HC Wainwright dropped their price objective on shares of AngioDynamics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, January 8th. Finally, Oppenheimer upgraded shares of AngioDynamics from a “market perform” rating to an “outperform” rating and set a $12.00 price target on the stock in a research note on Friday, April 5th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.25.

AngioDynamics Stock Down 0.9 %

Shares of ANGO traded down $0.06 during mid-day trading on Monday, hitting $6.31. 596,541 shares of the company’s stock were exchanged, compared to its average volume of 583,578. The firm has a fifty day moving average of $5.92 and a two-hundred day moving average of $6.47. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $11.38. The stock has a market cap of $252.78 million, a price-to-earnings ratio of -1.30 and a beta of 0.66.

Insider Activity at AngioDynamics

In other news, CEO James C. Clemmer purchased 10,000 shares of AngioDynamics stock in a transaction that occurred on Monday, April 8th. The stock was acquired at an average price of $6.70 per share, for a total transaction of $67,000.00. Following the transaction, the chief executive officer now owns 539,066 shares in the company, valued at $3,611,742.20. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in AngioDynamics by 6.4% in the 4th quarter. Vanguard Group Inc. now owns 2,268,461 shares of the medical instruments supplier’s stock valued at $17,785,000 after buying an additional 136,323 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in AngioDynamics by 19.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 30,951 shares of the medical instruments supplier’s stock valued at $243,000 after buying an additional 5,131 shares during the last quarter. Public Employees Retirement System of Ohio grew its stake in AngioDynamics by 21.4% in the 4th quarter. Public Employees Retirement System of Ohio now owns 76,539 shares of the medical instruments supplier’s stock valued at $600,000 after buying an additional 13,500 shares during the last quarter. Barclays PLC grew its stake in AngioDynamics by 131.3% in the 4th quarter. Barclays PLC now owns 88,263 shares of the medical instruments supplier’s stock valued at $692,000 after buying an additional 50,108 shares during the last quarter. Finally, Nuveen Asset Management LLC grew its stake in AngioDynamics by 20.6% in the 4th quarter. Nuveen Asset Management LLC now owns 430,429 shares of the medical instruments supplier’s stock valued at $3,375,000 after buying an additional 73,397 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.